Press Releases
Calidi is at the forefront of the genetic medicine revolution in cancer and other indications
Read the Latest
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
SAN DIEGO–(BUSINESS WIRE)–Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing…
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
Data supports CLD-101 and CLD-201’s first-in-class use of stem cells to protect and potentiate antitumor…
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic…
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
– Preclinical models have demonstrated the ability to resist oncolytic virus inactivation by human serum…